|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Hemagen Diagnostics, Inc. (HMGN) Successfully Completes Its Offer to Exchange 8% Senior Subordinated Secured Convertible Notes Due September 30, 2009
10/1/2009 10:38:05 AM
COLUMBIA, Md.--(BUSINESS WIRE)--William P. Hales, Chairman, President and CEO, of Hemagen Diagnostics, Inc., (OTCBB: HMGN) (the “Company”) today announced the successful completion of its Exchange Offer for $4,049,858.01 in principal amount of the outstanding 8% Senior Subordinated Secured Convertible Notes due September 30, 2009 (the “Old Notes”). Those tendering in the Exchange Offer received new 8% Senior Subordinated Secured Convertible Notes due September 30, 2014 (the “New Notes”) having the same principal amount as the Old Notes tendered for exchange. The Exchange Offer expired on Wednesday September 30, 2009, at Midnight and is effective as of that date. The Company has accepted all Old Notes tendered for exchange.
|
|
|
|
|
|
|
|
|
|
|